Zenith debt restructuring
Agreement reached with five banks to convert $25 mil. of short-term obligations to long-term debt ("The Pink Sheet" Aug. 17, p. 10). Zenith will make principal payments totaling $2.75 mil. through June 1988, with the balance due on Sept. 20, 1989. Interest is payable monthly at an initial rate of one point over prime, increasing to three points "if certain refinancings or assets sales are not effected by April 30, 1988".
You may also be interested in...
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.